mva-209-fsp
Vaccineexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2019 (NCT04041310)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05078866 | Phase 1/Phase 2 (Phase 2) | Mar 23, 2022 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT04041310 | Phase 1 | Sep 30, 2019 | Nouscom |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2022 |
| Nouscom | For profit | 1 | 1 | 1 | 2019 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1